AYAnna Yushkova

Anna Yushkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Yushkova has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

    by Natalya Risinskaya, Sofia Starchenko, Yulia Chabaeva, Abdulpatakh Abdulpatakhov, Ekaterina Kotova, Valeriya Surimova, Dmitry Bessmertnyy, Anastasia Kashlakova, Anastasia Vasileva, Zalina Fidarova, et al.

    Background: The tumor suppressor p53 is a critical regulator of gene expression in cancer, acting through binding to specific p53 response elements (REs). One of key RE rs4590952 is found in the KITLG gene. Aims: This study aimed to precisely investigate the allelic variants of the SNP rs4590952 within patient groups with acute leukemia and to analyze their association with the disease and response to therapy. A specific objective was to determine the frequency and nature of regions of homozygosity encompassing the KITLG locus. Methods: The study cohort included: 37 patients with Ph-negative B-ALL, 38 with T-ALL, and 35 with de novo intermediate-risk AML. A reference group of 200 healthy individuals without oncohematological disorders was used for comparison. Chromosomal microarray analysis (CMA) was performed using the CytoScan™ HT-CMA. Statistical analysis was performed using Python 3.12.4 and SAS 9.4. Results: The allele frequency (AF) of the G allele of rs4590952 was 0.785 in the reference group. Among patients, the AF was 0.833 in T-ALL, 0.757 in B-ALL, and 0.743 in AML. The frequency of copy-neutral loss of heterozygosity (cn-LOH) at 12q21.32, which results in the GG genotype, was significantly higher in the T-ALL group (45%) compared to the reference group (27%) (OR=0.4; 95% CI: 0.2–0.9; p=0.02). A significant association between MRD-positive status and cn-LOH KITLG was found specifically in the T-ALL group (OR=11; 95% CI: 2–62; p=0.005). Cn-LOH KITLG was also significantly associated with poor chemotherapy response in AML (p=0.01). Summary: The GG genotype of the p53 response element in KITLG (rs4590952) frequently arises from acquired cn-LOH at 12q21.32, observed in 45% of T-ALL and 26-27% of other cases. This treatment-response marker, present irrespective of leukemic status, warrants further validation in expanded cohorts.

  • Open Access

    Effect of DNA target size on the efficiency of chimerism measurement in circulating free plasma DNA

    by E. E. Nikulina, N. V. Risinskaya, O. E. Dubova, O. V. Sumtsova, Ya. G. Moysyuk, V. A. Vasilieva, М. В. Соловьева, A. A. Yushkova, I. S. Fevraleva, A. S. Skripkina, et al.

    Introduction. The analysis of free circulating DNA (cfDNA) holds promise for molecular diagnostics, but its fragmentation and low concentration can complicate PCR analysis.Objective. To investigate the effect of target length on the amplification efficiency of Y-chromosome markers from cfDNA.Material and methods. Fifty cfDNA samples were obtained from 39 patients: patients after liver transplantation (n=19), patients with acute leukemia after allogeneic hematopoietic stem cell transplantation (n=10), and pregnant women (n=10). In addition, we prepared 16 chimeric samples by sequential dilution of male cfDNA into female cfDNA from healthy donors. We determined the proportion of male cfDNA using the Y-chromosome marker S02, which is 211 bp in length as suggested by M. Alizadeh et al. We also modified Alizadeh's primer design to obtain a DNA target with a length of 138 bp. The proportion of male cfDNA was also determined by fragment analysis using the amelogenin Y marker (84 bp) from the COrDIS Plus kit (Gordiz LLC, Russia).Results. In the three groups of patients, amplification of male cfDNA was more efficient when shorter DNA targets were used (pConclusions. In the quantitative models tested so far, shorter PCR targets are preferred for the analysis of cfDNA.


  • Poster: ABCL-371 STR Loci Allele Imbalance at 9p24.1 in Primary Mediastinal B-Cell Lymphoma

    by Runiza Abdurashidova, Natalya Risinskaya, Yana Mangasarova, Anna Yushkova, Elena Nikulina, Irina Shupletsova, Alla Kovrigina, Vadim Surin, Hunan Julhakyan, Andrey Sudarikov

  • ABCL-371 STR Loci Allele Imbalance at 9p24.1 in Primary Mediastinal B-Cell Lymphoma

    by Runiza Abdurashidova, Natalya Risinskaya, Yana Mangasarova, Anna Yushkova, Elena Nikulina, Irina Shupletsova, Alla Kovrigina, Vadim Surin, Hunan Julhakyan, Andrey Sudarikov

  • Open Access

    Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome

    by Natalya V Risinskaya, Olga A. Gavrilina, Julia A. Chabaeva, Anna Yushkova, Andrey B Sudarikov, Sergei M. Kulikov, Elena N. Parovichnikova, Valery G. Savchenko

    Introduction: Loss of heterozygosity (LOH) was described for many malignancies including leukemia. Using chromosomal microarray analysis (CMA) we have shown preliminary (Risinskaya et al. HemaSphere, 2019, V.3, No S1, P.782) that LOH in STR loci in tumor cells with the normal karyotype represents the loss of extended chromosomal areas and could be associated with uniparental disomy of the entire chromosomal arm or the entire chromosome. Uniparental disomy results not only in the elimination of the wild type allele, but also may lead to the duplication of the mutant allele of certain candidate tumor gene(s). Retrospective analysis of archival samples have shown that in most cases STR loci absent at the relapse of disease were already lost at the onset of disease. We noted LOH at STR loci is especially frequent for relapsed ALL patients and could be used as prognostic factor for possible poor clinical outcome. The aim: To identify LOH in the blast cells of the patients with ALL at the onset of disease and to analyze therapy outcome relative to the patients without LOH. We expect LOH in the de novo ALL to be an unfavorable factor, and those patients possibly should be treated like high-risk group. Patients and Methods: This study includes a comparative analysis of the STR profiles of the DNA of tumor and normal cells from bone marrow samples on a cohort of 32 patients with de novo diagnosed Ph-negative ALL undergoing treatment according to the "RALL-2016" regimen at the National Research Center for Hematology (Moscow, Russia). Inclusion criteria: de novo diagnosed Ph-negative acute lymphoblastic leukemia (ALL) patients, 18-55 years old, intermediate risk group without MLL translocation t(4;11)(q21;q23), treatment by RALL-2016 protocol. Exclusion criteria: other diagnosis, adult patients older than 55 years, MLL translocation t(4;11)(q21;q23), pretreatment or treatment by other protocol. The presence of blast cells in bone marrow samples was confirmed morphologically. DNA was isolated from patient bone marrow samples taken at different disease stages. Control DNA samples were taken from blood of patients in complete remission and/or from buccal epithelium (buccal swab). STR-profiles were assessed by PCR with COrDIS Plus multiplex kit for amplification of 19 polymorphic STR-markers and amelogenin loci (Gordiz Ltd, Russia). The fragment analysis was performed on ABI3130 Genetic Analyzer. The data processing was accomplished using GeneMapper v.4-0 software. A multivariate survival analysis was used to assess the independent impact of the LOH as risk factor against the background of the abnormal tumor karyotype as standard factor for this cohort of patients. We have chosen Failure Free Survival (FFS) as primary endpoint for short-time follow-up and small patient sample size. Death from any reasons, relapse and second leukemia were chosen as failure events, survival time interval starts from begin of treatment. SAS V9/4 was used for statistical analysis of the data. Results: Of the 32 patients six were found with LOH in the certain STR loci (19%). Of these six, two were resistant to therapy and died from disease progression. One patient with LOH is currently in relapse and one patient with multiple LOH has a second leukemia (Fig.1a). Only two from six patients are "Failure Free" now, whereas only three patients from 26 in group without LOH died (two from infectious complications and one from GvHD after BMT). P value < 0,05 (Fig.1b). Conclusions: We have found statistically significant association of clinical failures with the LOH in STR loci measured at the onset of ALL. We assume that LOH is an unfavorable prognostic factor for de novo ALL patients and could be used for risk stratification and choice of adequate therapy implying allogeneic hematopoietic stem cells transplantation or modern innovative therapy approaches.